GOSS vs. ADPT, JANX, ABCL, ETNB, VERA, ANIP, BHVN, EWTX, TVTX, and COGT
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Adaptive Biotechnologies (ADPT), Janux Therapeutics (JANX), AbCellera Biologics (ABCL), 89BIO (ETNB), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs. Its Competitors
Gossamer Bio (NASDAQ:GOSS) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.
Gossamer Bio has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.
Gossamer Bio presently has a consensus price target of $8.25, indicating a potential upside of 363.48%. Adaptive Biotechnologies has a consensus price target of $10.57, indicating a potential downside of 0.83%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Adaptive Biotechnologies.
Gossamer Bio has a net margin of -41.12% compared to Adaptive Biotechnologies' net margin of -74.84%. Adaptive Biotechnologies' return on equity of -62.79% beat Gossamer Bio's return on equity.
In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Gossamer Bio. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 1 mentions for Gossamer Bio. Adaptive Biotechnologies' average media sentiment score of 0.95 beat Gossamer Bio's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Gossamer Bio beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 7/24/2025 by MarketBeat.com Staff
Free GOSS Stock Alerts